Claraphi Advisory Network LLC bought a new stake in Heron Therapeutics Inc (NASDAQ:HRTX) in the 4th quarter, HoldingsChannel reports. The fund bought 18,500 shares of the biotechnology company’s stock, valued at approximately $335,000.
Several other hedge funds have also recently made changes to their positions in HRTX. Janus Henderson Group PLC purchased a new position in shares of Heron Therapeutics in the second quarter valued at $78,134,000. Perceptive Advisors LLC purchased a new position in shares of Heron Therapeutics in the third quarter valued at $5,329,000. Vanguard Group Inc. boosted its stake in shares of Heron Therapeutics by 11.8% in the second quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock valued at $29,036,000 after purchasing an additional 221,362 shares during the period. Rubric Capital Management LP boosted its stake in shares of Heron Therapeutics by 11.8% in the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock valued at $30,685,000 after purchasing an additional 200,000 shares during the period. Finally, Chartwell Investment Partners LLC purchased a new position in shares of Heron Therapeutics in the third quarter valued at $2,340,000. Institutional investors and hedge funds own 98.37% of the company’s stock.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the transaction, the vice president now directly owns 7,584 shares in the company, valued at approximately $151,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 19.93% of the company’s stock.
Heron Therapeutics Inc (NASDAQ HRTX) opened at $20.70 on Tuesday. Heron Therapeutics Inc has a 52 week low of $12.70 and a 52 week high of $24.80. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62. The company has a market cap of $1,130.00, a price-to-earnings ratio of -5.46 and a beta of 1.87.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The firm had revenue of $8.57 million for the quarter, compared to the consensus estimate of $8.12 million. equities research analysts predict that Heron Therapeutics Inc will post -3.37 earnings per share for the current fiscal year.
Several research analysts have recently weighed in on the stock. Mizuho restated a “buy” rating and issued a $28.00 target price on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Friday, October 20th. Cowen restated a “buy” rating and issued a $40.00 target price on shares of Heron Therapeutics in a research note on Monday, November 6th. Leerink Swann assumed coverage on shares of Heron Therapeutics in a research note on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 target price for the company. Finally, BidaskClub upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 20th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Heron Therapeutics currently has an average rating of “Buy” and an average price target of $28.82.
TRADEMARK VIOLATION WARNING: This piece was published by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thestockobserver.com/2018/02/06/claraphi-advisory-network-llc-acquires-new-stake-in-heron-therapeutics-inc-hrtx.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.